EUR 15.02
(0.47%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 32.92 Million EUR | -8.81% |
2022 | 36.06 Million EUR | 17.39% |
2021 | 30.72 Million EUR | 18.72% |
2020 | 25.87 Million EUR | 7.54% |
2019 | 24.06 Million EUR | 50.87% |
2018 | 15.94 Million EUR | 17.97% |
2017 | 13.52 Million EUR | 30.14% |
2016 | 10.38 Million EUR | 33.0% |
2015 | 7.81 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 FY | 32.88 Million EUR | -8.81% |
2023 Q2 | 16.28 Million EUR | 0.0% |
2023 Q4 | 15.76 Million EUR | 0.0% |
2022 Q2 | 18.54 Million EUR | 0.0% |
2022 Q4 | 17.51 Million EUR | 0.0% |
2022 FY | 36.06 Million EUR | 17.39% |
2021 Q2 | 14.65 Million EUR | 0.0% |
2021 Q4 | 16.06 Million EUR | 0.0% |
2021 FY | 30.72 Million EUR | 18.72% |
2020 FY | 25.87 Million EUR | 7.54% |
2020 Q4 | 15.44 Million EUR | 0.0% |
2020 Q2 | 10.44 Million EUR | 0.0% |
2019 Q4 | 12.52 Million EUR | 0.0% |
2019 FY | 24.06 Million EUR | 50.87% |
2019 Q2 | 11.44 Million EUR | 0.0% |
2018 Q4 | 11.03 Million EUR | 100.0% |
2018 Q3 | 5.51 Million EUR | -47.97% |
2018 Q1 | 5.3 Million EUR | -40.41% |
2018 Q2 | 10.6 Million EUR | 100.0% |
2018 FY | 15.94 Million EUR | 17.97% |
2017 Q2 | 6.6 Million EUR | 100.0% |
2017 Q4 | 8.89 Million EUR | 100.0% |
2017 FY | 13.52 Million EUR | 30.14% |
2017 Q3 | 4.44 Million EUR | -32.65% |
2017 Q1 | 3.3 Million EUR | 0.0% |
2016 FY | 10.38 Million EUR | 33.0% |
2015 FY | 7.81 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -688.174% |
ABIVAX Société Anonyme | 127.37 Million EUR | 74.154% |
Adocia SA | 15.62 Million EUR | -110.647% |
Aelis Farma SA | 18.81 Million EUR | -74.94% |
Biophytis S.A. | 14.33 Million EUR | -129.694% |
Advicenne S.A. | 8.21 Million EUR | -300.755% |
genOway Société anonyme | 16.73 Million EUR | -96.687% |
IntegraGen SA | 5.35 Million EUR | -515.076% |
Medesis Pharma S.A. | 1.56 Million EUR | -2004.218% |
Neovacs S.A. | 10.34 Million EUR | -218.285% |
NFL Biosciences SA | 4.37 Million EUR | -652.614% |
Plant Advanced Technologies SA | 2.76 Million EUR | -1090.734% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -1816.337% |
Sensorion SA | 27.05 Million EUR | -21.691% |
Theranexus Société Anonyme | 3 Million EUR | -995.579% |
TME Pharma N.V. | 5.49 Million EUR | -498.908% |
Valbiotis SA | 9.86 Million EUR | -233.59% |
TheraVet SA | 1.64 Million EUR | -1902.174% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | -62.018% |
DBV Technologies S.A. | 89.4 Million EUR | 63.177% |
Genfit S.A. | 54.8 Million EUR | 39.928% |
GeNeuro SA | 14.35 Million EUR | -129.305% |
Innate Pharma S.A. | 64.57 Million EUR | 49.013% |
Inventiva S.A. | 120.18 Million EUR | 72.607% |
MaaT Pharma SA | 21.59 Million EUR | -52.431% |
Nanobiotix S.A. | 58.92 Million EUR | 44.131% |
OSE Immunotherapeutics SA | 23.58 Million EUR | -39.565% |
Poxel S.A. | 28.76 Million EUR | -14.452% |
GenSight Biologics S.A. | 32.66 Million EUR | -0.802% |
Transgene SA | 31.23 Million EUR | -5.414% |
Valneva SE | 134.92 Million EUR | 75.6% |